Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Oncogene
2012 Jan 19;313:269-81. doi: 10.1038/onc.2011.245.
Show Gene links
Show Anatomy links
Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells.
Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, Glasgow E, Dakshanamurthy S, Lee HS, Daar I, Toretsky JA, Khanna C, Uren A.
???displayArticle.abstract???
Ezrin is a multifunctional protein that connects the actin cytoskeleton to the extracellular matrix through transmembrane proteins. High ezrin expression is associated with lung metastasis and poor survival in cancer. We screened small molecule libraries for compounds that directly interact with ezrin protein using surface plasmon resonance to identify lead compounds. The secondary functional assays used for lead compound selection included ezrin phosphorylation as measured by immunoprecipitation and in vitro kinase assays, actin binding, chemotaxis, invasion into an endothelial cell monolayer, zebrafish and Xenopus embryonic development, mouse lung organ culture and an in vivo lung metastasis model. Two molecules, NSC305787 and NSC668394, that directly bind to ezrin with low micromolar affinity were selected based on inhibition of ezrin function in multiple assays. They inhibited ezrin phosphorylation, ezrin-actin interaction and ezrin-mediated motility of osteosarcoma (OS) cells in culture. NSC305787 mimicked the ezrin morpholino phenotype, and NSC668394 caused a unique developmental defect consistent with reduced cell motility in zebrafish. Following tail vein injection of OS cells into mice, both molecules inhibited lung metastasis of ezrin-sensitive cells, but not ezrin-resistant cells. The small molecule inhibitors NSC305787 and NSC668394 demonstrate a novel targeted therapy that directly inhibits ezrin protein as an approach to prevent tumor metastasis.
Bacci,
Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients.
2006, Pubmed
Bacci,
Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients.
2006,
Pubmed Boger,
Streptonigrin and lavendamycin partial structures. Probes for the minimum, potent pharmacophore of streptonigrin, lavendamycin, and synthetic quinoline-5,8-diones.
1987,
Pubmed Bretscher,
ERM proteins and merlin: integrators at the cell cortex.
2002,
Pubmed Chen,
Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival.
2008,
Pubmed Dunn,
Metastatic osteosarcoma to lung: a clinicopathologic study of surgical biopsies and resections.
1977,
Pubmed Elliott,
The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells.
2005,
Pubmed Elzagheid,
Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer.
2008,
Pubmed Fehon,
Organizing the cell cortex: the role of ERM proteins.
2010,
Pubmed Ferrari,
Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma.
2007,
Pubmed Fiévet,
ERM proteins in epithelial cell organization and functions.
2007,
Pubmed Fivash,
BIAcore for macromolecular interaction.
1998,
Pubmed Gary,
Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site.
1995,
Pubmed Gautreau,
Morphogenic effects of ezrin require a phosphorylation-induced transition from oligomers to monomers at the plasma membrane.
2000,
Pubmed Gautreau,
Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway.
1999,
Pubmed Geiger,
Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas.
2000,
Pubmed Hirao,
Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway.
1996,
Pubmed Khanna,
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis.
2004,
Pubmed Khanna,
Metastasis-associated differences in gene expression in a murine model of osteosarcoma.
2001,
Pubmed Kimmel,
Stages of embryonic development of the zebrafish.
1995,
Pubmed
,
Xenbase Köbel,
Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma.
2006,
Pubmed Legg,
Identification and functional analysis of the ezrin-binding site in the hyaluronan receptor, CD44.
1998,
Pubmed Link,
Identification of regulators of germ layer morphogenesis using proteomics in zebrafish.
2006,
Pubmed Lipinski,
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.
2001,
Pubmed Longhi,
Primary bone osteosarcoma in the pediatric age: state of the art.
2006,
Pubmed Louvet-Vallée,
ERM proteins: from cellular architecture to cell signaling.
2000,
Pubmed Mäkitie,
Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma.
2001,
Pubmed Malmqvist,
BIACORE: an affinity biosensor system for characterization of biomolecular interactions.
1999,
Pubmed Matsui,
Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association.
1998,
Pubmed Mendoza,
Modeling metastasis biology and therapy in real time in the mouse lung.
2010,
Pubmed Ohnmacht,
Antimalarials. 7. Bis(trifluoromethyl)- -(2-piperidyl)-4-quinolinemethanols.
1971,
Pubmed Pang,
Expression of ezrin in prostatic intraepithelial neoplasia.
2004,
Pubmed Park,
Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma.
2006,
Pubmed Reczek,
Identification of EBP50: A PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family.
1997,
Pubmed Ren,
The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC.
2009,
Pubmed Rosen,
Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.
1982,
Pubmed ten Klooster,
Mst4 and Ezrin induce brush borders downstream of the Lkb1/Strad/Mo25 polarization complex.
2009,
Pubmed Wan,
Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin.
2009,
Pubmed Wang,
Development and testing of a general amber force field.
2004,
Pubmed Weng,
Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas.
2005,
Pubmed Yu,
Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators.
2004,
Pubmed Zhang,
Critical role of notch signaling in osteosarcoma invasion and metastasis.
2008,
Pubmed
